6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trialHelena Earl, Joanne Cliff, Karen McAdam et al.|The Lancet|2019Cited by 287
Epirubicin and Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy for Early Breast CancerChristopher Poole, Christopher Twelves, Helena Earl et al.|New England Journal of Medicine|2006Cited by 189